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CD38 promotes pristane-induced 
chronic inflammation and increases 
susceptibility to experimental lupus 
by an apoptosis-driven and TRPM2-
dependent mechanism
Sonia García-Rodríguez1, Antonio Rosal-Vela1, Davide Botta  2, Luz M. Cumba Garcia1,9,  
Esther Zumaquero2, Verónica Prados-Maniviesa1, Daniela Cerezo-Wallis1,10, Nicola Lo  
Buono  1,11, José-Ángel Robles-Guirado1, Salvador Guerrero3, Elena González-Paredes1, 
Eduardo Andrés-León  4, Ángel Corbí5, Matthias Mack6, Friedrich Koch-Nolte7, Ramón  
Merino8, Mercedes Zubiaur1, Frances E. Lund2 & Jaime Sancho  1
In this study, we investigated the role of CD38 in a pristane-induced murine model of lupus. CD38-
deficient (Cd38−/−) but not ART2-deficient (Art2−/−) mice developed less severe lupus compared to 
wild type (WT) mice, and their protective phenotype consisted of (i) decreased IFN-I-stimulated gene 
expression, (ii) decreased numbers of peritoneal CCR2hiLy6Chi inflammatory monocytes, TNF-α-
producing Ly6G+ neutrophils and Ly6Clo monocytes/macrophages, (iii) decreased production of anti-
single-stranded DNA and anti-nRNP autoantibodies, and (iv) ameliorated glomerulonephritis. Cd38−/− 
pristane-elicited peritoneal exudate cells had defective CCL2 and TNF-α secretion following TLR7 
stimulation. However, Tnf-α and Cxcl12 gene expression in Cd38−/− bone marrow (BM) cells was intact, 
suggesting a CD38-independent TLR7/TNF-α/CXCL12 axis in the BM. Chemotactic responses of Cd38−/− 
Ly6Chi monocytes and Ly6G+ neutrophils were not impaired. However, Cd38−/− Ly6Chi monocytes 
and Ly6Clo monocytes/macrophages had defective apoptosis-mediated cell death. Importantly, 
mice lacking the cation channel TRPM2 (Trpm2−/−) exhibited very similar protection, with decreased 
numbers of PECs, and apoptotic Ly6Chi monocytes and Ly6Clo monocytes/macrophages compared to 
WT mice. These findings reveal a new role for CD38 in promoting aberrant inflammation and lupus-like 
autoimmunity via an apoptosis-driven mechanism. Furthermore, given the implications of CD38 in the 
activation of TRPM2, our data suggest that CD38 modulation of pristane-induced apoptosis is TRPM2-
dependent.
Systemic lupus erythematosus (SLE) is a chronic multi-organ inflammatory disease in which autoantibod-
ies against nucleic acid–protein complexes, such as chromatin and ribonucleoproteins (RNPs), cause disease 
by forming immune complexes that deposit in target tissues. A type I IFN–dependent lupus syndrome closely 
resembling human SLE develops in BALB/c, C57BL/6 (B6), and other strains of mice with chronic inflammation 
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following an intraperitoneal injection of pristane (2,6,10,14-tetramethylpentadecane)1,2,3. Autoantibody produc-
tion and glomerulonephritis in pristane-induced lupus require Toll-like receptor 7 (TLR-7)–mediated type I IFN 
production driven by the transcription factors IFN regulatory factor 5 (IRF-5) and IRF-73.
CD38 is a type II transmembrane protein, which can function as a receptor or as an ectoenzyme4–6. In fact, 
CD38 is considered a multifunctional enzyme capable of recognizing nicotinamide adenine dinucleotide (NAD) 
and nicotinamide adenine dinucleotide phosphate (NADP) as substrates, and generating four products, namely 
nicotinamide, adenosine diphosphate ribose (ADPR), which is an activator of the redox-sensitive cation channel 
Transient Receptor Potential Melastatin 2 (TRPM2), and cyclic ADPR (cADPR) and nicotinic acid adenine dinu-
cleotide phosphate (NAADP), which are potent Ca2+-mobilizing intracellular messengers. CD38 is expressed 
in hematopoietic and non-hematopoietic tissues, and has been shown to regulate neutrophil migration and DC 
trafficking7–11, and that this regulation occurred via the modulation of extracellular calcium by TRPM212. CD38 
ligation with anti-CD38 antibodies stimulates cell proliferation, adhesion, apoptosis and cytokine secretion in 
different cell types6. In human T and B cells, upon receptor stimulation CD38 leads to PKB/AKT and ERK acti-
vation13,14. In regulatory T cells (Tregs), expression of CD38 is regulated by phosphoinositide 3-kinase (PI3K) 
p110δ15. Furthermore, CD19+CD24hi B cells that express high levels of CD38, and which exhibit regulatory capac-
ity in healthy individuals, produced less IL-10 and lacked suppressive capacity in SLE patients16. Moreover, CD38 
plays an important role in modulating antigen-mediated T-cell responses at the immunological synapse, where 
CD38 is actively recruited by a Lck-mediated mechanism17. CD38 is a pathogenic and prognostic marker in 
human leukemias (MM, B-CLL, AML)18.
Increased CD38 surface expression in SLE T cells is more prevalent in clinically active SLE patients, while high 
levels of anti-CD38 autoantibodies are more frequent in quiescent SLE patients with low levels of anti-dsDNA 
autoantibodies19. Likewise, increased mRNA expression of CD38 in SLE T cells correlates with increased severity 
of the disease, and is considered part of a NAD(P)-binding domain gene expression signature associated with 
SLE20. Increased CD38 expression in SLE T cells could be the consequence of the action of pro-inflammatory 
cytokines such as TNF-α and IFN-γ, and is indicative of SLE patients with a more active disease, and with an overt 
abnormal Th2 and Th1 cytokine profile19. On the other hand, it has been previously reported that CD38-deficient 
(Cd38−/−) mice develop an attenuated form of Collagen-induced arthritis (CIA) compared to WT mice21 that is 
accompanied by a limited joint induction of IL-1β and IL-6 expression, by the lack of induction of IFN-γ expres-
sion in the joints, and by a reduction in the percentages of invariant natural killer T (iNKT) cells in the spleen. 
Immunized Cd38−/− mice produce high levels of circulating IgG1 and low levels of IgG2a and anti-collagen II 
antibodies, which correlate with reduced frequencies of Th1 cells in the draining lymph nodes. Therefore, CD38 
participates in the pathogenesis of CIA by controlling the number of iNKT cells and promoting Th1 inflammatory 
responses21.
In the present study, we examined the role of CD38 during the early inflammatory phase of pristane-induced 
lupus, a murine model of systemic lupus erythematosus (SLE). We show that pristane-treated Cd38−/− mice, but 
not Art2−/− mice, had impaired recruitment of peritoneal exudate cells (PECs) compared to WT mice, particu-
larly Ly6Chi monocytes and Ly6Clo monocytes/macrophages and Ly6G+ neutrophils, and that this decreased 
cellularity in the peritoneal cavity (PC) was not due to a defective chemotaxis of these cells but instead due 
to decreased apoptosis-mediated cell death of PECs, characterized by defective caspase-3 activation and 
decreased levels of phosphorylated Akt. We identified Ly6Chi monocytes and Ly6Clo monocytes/macrophages 
as the apoptosis-resistant cell populations. Given the implication of CD38 in the activation of the cation channel 
TRPM2 via the production of cADPR/ADPR, we analysed the phenotype of pristane-treated Trpm2−/− mice, and 
observed similar protection from apoptosis-mediated death of PECs in these mice. Furthermore, the produc-
tion of anti-single-stranded DNA and anti-nuclear RNP (nRNP) autoantibodies, the development of glomeru-
lonephritis, and the expression of IFN-I-stimulated genes (ISGs) were also greatly attenuated in pristane-treated 
Cd38−/− mice. Hence, our data suggest that CD38 deficiency protects mice from pristane-induced lupus in a 
TRPM2-dependent manner by reducing the number of intraperitoneal apoptotic cells, which are the primary 
source of autoantigens in this murine model of SLE.
Results
CD38 deficiency alters the chronic inflammatory response to pristane by an ART2-independent 
mechanism. It has previously been reported that a subset of inflammatory monocytes expressing high levels 
of CCR2 and Ly6C is recruited to the peritoneum in response to CCL2 (MCP-1) and is a major source of IFN-I 
in pristane-treated mice22. The effect of CD38 deficiency on the recruitment of inflammatory Ly6Chi monocytes 
(CD11b+Ly6ChiLy6G−), Ly6Clo monocytes (CD11b+Ly6CloLy6G−), and neutrophils (CD11b+Ly6CloLy6G+) was 
examined 2 weeks following an intraperitoneal (i.p.) injection of pristane. Consistent with previous findings22,23, 
most pristane-elicited monocytes in WT mice expressed high levels of Ly6C (Fig. 1a). However, PECs from pris-
tane-treated Cd38−/− mice contained significantly lower frequencies and numbers of Ly6Chi monocytes compared 
to pristane-treated WT controls (Fig. 1b). Moreover, PECs from Cd38−/− mice contained a significantly higher 
frequency of Ly6Clo monocytes compared to WT mice (Fig. 1c). The relative frequency of neutrophils, on the 
other hand, was comparable to that in WT mice (Fig. 1d).
NAD released during inflammation participates in the in vivo regulation of T cell homeostasis through an 
ART2-dependent and P2X7-mediated mechanism24, that is commonly referred to as NAD-induced cell death 
(NICD)25). NICD is controlled in part by CD38, which limits substrate availability for ART2 by hydrolysing 
extracellular NAD26. In the absence of CD38, ART2 preferentially activates apoptotic deletion of peripheral iNKT 
cells, especially the CD4+ subset, resulting in the reduction of NKT cells under steady-state conditions21. Since 
reduced numbers and/or functions of NKT cells have been shown to exacerbate pristane-induced lupus nephri-
tis27, we assessed whether the absence of ART2, or the absence of both CD38 and ART2, had any influence on the 
persistent, pristane-induced inflammatory cell influx into the peritoneal cavity. ART2-deficient (Art2−/−) mice 
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Figure 1. Altered pristane-induced chronic inflammation in Cd38−/− mice. (a) Flow cytometric analysis of 
Ly6C and Ly6G expression on CD11b+-gated PECs at 2-weeks post pristane treatment. Contour plots show 
the frequencies of Ly6Chi monocytes, Ly6G+ neutrophils, and Ly6Clo monocytes/macrophages as a percentage 
of total CD11b+ PECs from WT, Cd38−/−, Art2−/−, and Cd38−/−Art2−/− mice. Contour plots shown are 
representative of 3 independent experiments. (b–d) Frequencies of Ly6Chi monocytes (b) Ly6Clo monocytes/
macrophages (c) and Ly6G+ neutrophils (d) as a percentage of total PECs from WT, Cd38−/−, Art2−/−, and 
Cd38−/−Art2−/− mice. Data are shown as the mean ± SE (n = 7–9 mice/group). (e) Absolute numbers of total 
PECs at 0-, 1-, 2-, 4-, and 16-weeks post pristane treatment. Data are shown as mean ± SE (n = 5–14 mice/
group). (f–h) Numbers of Ly6Chi monocytes (f), Ly6Clo monocytes/macrophages (g) and Ly6G+ neutrophils 
(h) at 2- and 4-weeks post pristane treatment. Data are shown as the mean ± SE (n = 7–9 mice/group). All P 
values were determined by 2-way ANOVA with the Dunnett’s multiple comparisons test. *P < 0.05 **P < 0.01 
***P < 0.001 ****P < 0.0001.
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showed an intact influx of Ly6Chi monocytes at 2-weeks post-pristane treatment that was similar to WT mice, 
whereas Cd38−/−Art2−/− double knockout mice exhibited a decreased frequency of recruited Ly6Chi monocytes 
that was similar to that observed in Cd38−/− mice (Fig. 1b). Therefore, the defective pristane-induced influx of 
Ly6Chi monocytes into the peritoneal cavity seems to be CD38-dependent but ART2-independent.
The pristane-induced influx of cells into the PC of Cd38−/− and WT mice followed similar kinetics. Indeed, 
both groups of mice had increased numbers of PECs following pristane treatment, which peaked at 4 weeks and 
returned to basal levels by 16 weeks (Fig. 1e). No significant differences were observed in the number of PECs 
between the two groups of mice at 1-week post treatment, suggesting that Cd38−/− mice exhibit an intact early 
response to pristane. However, at 2- and 4-weeks post treatment, the numbers of PECs were significantly lower 
in Cd38−/− mice compared to WT mice, reaching similar numbers only at 16-weeks post treatment, when the 
inflammatory response is less severe and the symptoms of lupus begin to manifest28.
The differences in total numbers of PECs between pristane-treated WT and Cd38−/− mice had a clear effect on 
the absolute numbers of the Ly6Chi monocyte, Ly6Clo monocyte/macrophage and Ly6G+ neutrophil cell subsets 
analysed. We observed a significantly lower number of Ly6Chi monocytes in Cd38−/− mice compared to WT mice 
at both 2-weeks and 4-weeks post pristane treatment (Fig. 1f), while decreased numbers of Ly6Clo monocytes and 
Ly6G+ neutrophils in Cd38−/− mice appeared only at 4-weeks post pristane (Fig. 1g and h). Hence, our data con-
vincingly show that pristane induces a chronic inflammatory response in Cd38−/− mice, albeit more attenuated 
than in WT mice.
Pristane-elicited PECs from Cd38−/− mice exhibit defective caspase-3 activation. To explore the 
possibility that altered apoptosis may be responsible for the decreased number of PECs in Cd38−/− mice observed 
at 2- and 4-weeks post pristane treatment, we isolated WT and Cd38−/− pristane-elicited PECs and compared 
their apoptotic phenotype by simultaneously staining these cells with Annexin V-FITC (AnnV) and the cell 
viability dye 7-aminoactinomycin D (7-AAD) (Fig. 2a). PECs from 1-week pristane-treated WT and Cd38−/− 
mice showed no differences in the numbers of early apoptotic (AnnVlo7-AAD−), late apoptotic (AnnVhi7-AAD−) 
and end-stage apoptotic/dead (AnnVhi7-AAD+) cells (Fig. 2b, lower left panel). In contrast, PECs from 2-weeks 
pristane-treated Cd38−/− mice had a significant decrease in the number of early apoptotic cells and a modest 
decrease (P = 0.0651) in the number of late apoptotic cells (Fig. 2b, lower right panel).
Normally, cleavage of caspase-3 by caspase-8 or caspase-9 is required for the commitment of cells to apopto-
sis. The processed form of caspase-3 consists of a large (17 kDa) and a small (12 kDa) subunit, which associate to 
form the active enzyme. To assess whether cleaved caspase-3 was detected in PECs from pristane-treated mice, 
we subjected lysates from 2-, 4- and 8-weeks pristane-elicited PECs to Western blotting using an antibody that 
recognized the 17 kDa subunit of active caspase-3. The amount of cleaved caspase-3 in WT PECs peaked at 2 
weeks, and was found to be 4-fold higher relative to Cd38−/− PECs at this time point (Fig. 2c, lower left panel).
Cell survival requires the active inhibition of apoptosis, which is accomplished by the phosphorylation of 
pro-apoptotic factors via the activation of Erk1/2 or Akt, or by promoting the expression of anti-apoptotic factors. 
We, therefore, measured and compared the levels of phospho-Erk1/2 (pErk), phospho-Akt (pAkt) and the key 
anti-apoptotic player Mcl-1 in pristane-elicited PECs. WT and Cd38−/− PECs reached similar maximal levels of 
pErk1/2 at 4-weeks post-pristane treatment but differed in phosphorylation kinetics (Fig. 2c, lower right panel). 
Specifically, WT PECs had slow and sustained ERK1/2 phosphorylation that was low at 2 weeks, reached a peak 
at 4 weeks and remained maximal at 8 weeks post-pristane treatment. Cd38−/− PECs, on the other hand, had 
rapid and transient ERK1/2 phosphorylation that was 2.2-fold higher at 2 weeks, reached a peak at 4 weeks, and 
declined 2.5-fold at 8 weeks compared to WT PECs. Comparison of pAkt levels revealed decreased phospho-
rylation of Akt in Cd38−/− PECs at 1-week post-pristane treatment, which was 3.7-fold lower than that in WT 
PECs (Fig. 2d, lower left panel). The phosphorylation kinetics of Akt, however, did not differ between WT and 
Cd38−/− PECs, and correlated with those of caspase-3. Furthermore, Mcl-1 protein levels were increased in both 
WT and Cd38−/− PECs, with a maximum at 4-weeks post pristane treatment and a kinetic profile very similar to 
that of pERK1/2 (Fig. 2d, lower right panel). Images of the entire non-cropped membranes from the Western blot 
analyses have been included as supplementary data in Figs S10–S12.
Cd38−/− and Trpm2−/− Ly6Chi monocytes and Ly6Clo monocytes/macrophages exhibit defective 
pristane-induced apoptosis. To examine whether there was a specific peritoneal cell subset in Cd38−/− 
or TRPM2-deficient (Trpm2−/−) mice with defective pristane-induced and apoptosis-mediated cell death, we 
isolated WT, Cd38−/− and Trpm2−/− PECs from 1- and 2-weeks pristane-treated mice and assessed early apop-
totic (AnnV+7-AAD−), late apoptotic (AnnV+7-AAD+) and necrotic (AnnV−7-ADD+) cells within 3 major 
cell populations, namely Ly6Chi monocytes, Ly6Clo monocytes/macrophages, and Ly6G+ neutrophils (Fig. 3a 
and e). At 1-week post-pristane treatment, Cd38−/− and Trpm2−/− mice had decreased numbers of necrotic and 
late apoptotic Ly6Chi monocytes and Ly6Clo monocytes/macrophages compared to WT mice (Fig. 3b and c), 
while the numbers of necrotic/apoptotic Ly6G+ neutrophils were similar (Fig. 3d). The Ly6Clo cell population 
was further characterized as 2 distinct subsets based on side scatter (SSC), which is indicative of granularity, 
and identified accordingly as Ly6CloSSChi cells (macrophages) and Ly6CloSSClo cells (monocytes) (Fig. S1A). 
Interestingly, the defective apoptosis/necrosis exhibited by Cd38−/− and Trpm2−/− Ly6Clo cells at 1-week post 
treatment corresponded to that of the SSChi subset (Fig. S1B), which comprised the majority of the CD11b+ 
cells (Fig. S1A). A similar defective apoptotic phenotype in Cd38−/− and Trpm2−/− Ly6Chi monocytes was also 
observed at 2-weeks post pristane treatment (Fig. 3f). Indeed, Cd38−/− and Trpm2−/− mice had significantly lower 
numbers of early- and late-apoptotic Ly6Chi monocytes compared to WT mice. No differences were detected in 
apoptotic Ly6Clo monocytes/macrophages between the 3 groups of mice at this time point (Fig. 3g), but a modest 
increase in early-apoptotic Cd38−/− and Trpm2−/− Ly6G+ neutrophils was observed (Fig. 3h). These data sug-
gest that pristane-induced apoptosis/necrosis of Ly6Chi monocytes and Ly6Clo monocytes/macrophages is both 
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CD38- and TRPM2-dependent. This link between CD38 and TRPM2 is also supported by additional phenotypic 
similarities between pristane-treated Cd38−/− and Trpm2−/− mice, specifically their decreased numbers of total 
PECs, and decreased frequency and numbers of Ly6Chi monocytes recruited to the PC (Fig. S2). Interestingly, at 
2-weeks post-pristane treatment, Art2−/− mice showed a higher frequency of apoptotic Ly6Chi monocytes and 
Figure 2. Defective caspase-3 activation in pristane-elicited PECs from Cd38−/− mice. (a) Flow cytometric 
analysis of Annexin V (AnnV) and 7-AAD staining on PECs from 1-week pristane treated (upper panels) 
and 2-weeks pristane-treated (lower panels) WT and Cd38−/− mice. Frequencies of early apoptotic (AnnVlo7-
AAD−), late apoptotic (AnnVhi7-AAD−) and necrotic cells (AnnVhi7-AAD+) are shown. (b) Frequencies 
(top panels) and absolute numbers (bottom panels) of necrotic, early apoptotic, and late apoptotic PECs from 
1- and 2-weeks pristane-treated WT and Cd38−/− mice. Closed (WT) and open (Cd38−/−) bars represent the 
mean and the error bars indicate SE (n = 5-6 mice/group. P values were determined by 2-way ANOVA with the 
Bonferroni’s multiple comparisons test. ****P < 0.0001. (c) Lysates from 2-, 4- and 8-weeks pristane-elicited 
PECs were subjected to Western blotting using antibodies specific for active caspase-3, phospho-Erk1/2 (Thr185/
Tyr187), total Erk1/2, and the corresponding stain-free areas of the PVDF membrane before blotting. Each lane 
represents a pool of 3 lysates from 3 mice/group. Densitometric analyses of the amount of active caspase-3 or 
phosphorylated Erk1/2 were done using the Image Lab software (Bio-Rad Laboratories). In the lower left and 
right panels the normalized amount of active caspase-3 and the pErk/Erk ratios are shown, respectively. (d) 
Lysates from 1-, 2-, 4- and 8-weeks pristane-elicited PECs were subjected to Western blotting using antibodies 
specific for phosphorylated Akt and total Akt (upper left panel) or antibodies specific for Mcl-1 (upper right 
panel). In the lower left and right panels the pAkt/Akt ratios and normalized amounts of Mcl-1 are shown, 
respectively. In all blots, Stain-Free technology was used as the loading control method88. Images of the entire 
non-cropped membranes have been included as supplementary data in Figs S10–S12.
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Ly6Clo monocytes/macrophages compared to Cd38−/− and Cd38−/−Art2−/− double knockout mice (Fig. S3), pro-
viding further evidence that ART2 does not play a role in this process.
Distinct clustering of mice based on ISG expression in pristane-elicited PECs. We meas-
ured and compared the expression of ISGs in PECs from 2-weeks pristane-treated WT, Cd38−/−, Art2−/−, and 
Figure 3. Defective pristane-induced apoptosis in Ly6Chi monocytes and Ly6Clo monocytes/macrophages 
from Cd38−/− and Trpm2−/− mice. (a,e) Flow cytometric analysis of Annexin V (AnnV) and 7-AAD staining 
of Ly6Chi monocytes, Ly6Clo monocytes/macrophages and Ly6G+ neutrophils from 1-week pristane-treated 
(a) and 2-weeks pristane-treated (e) WT, Cd38−/− and Trpm2−/− mice. Frequencies of AnnV−7-AAD− live 
cells, AnnV+7-AAD− early apoptotic cells, AnnV+7-AAD+ end-stage apoptotic/dead cells and AnnV−7-
AAD+ necrotic cells are shown as percentages of the Ly6Chi, Ly6Clo and Ly6G+ parent cell populations ± SD 
(n = 5 mice/group). Dot plots shown are representative of 2 independent experiments. (b–d) Numbers of 
early apoptotic, late apoptotic and necrotic Ly6Chi monocytes (b), Ly6Clo monocytes/macrophages (c) and 
Ly6G+ neutrophils (d) from 1-week pristane-treated WT, Cd38−/−, and Trmp2−/− mice. Data are shown as 
the mean ± SD (n = 5 mice/group). (f–h) Numbers of early apoptotic, late apoptotic and necrotic Ly6Chi 
monocytes (f), Ly6Clo monocytes/macrophages (g) and Ly6G+ neutrophils (h) from 2-weeks pristane-treated 
WT, Cd38−/−, and Trmp2−/− mice. Data are shown as the mean ± SD (n = 7 mice/group). *P < 0.05 **P < 0.01 
***P < 0.001 ****P < 0.0001 by 2-way ANOVA with the Dunnett’s multiple comparisons test.
www.nature.com/scientificreports/
7SCIENTIFIC RepoRts |  (2018) 8:3357  | DOI:10.1038/s41598-018-21337-6
Cd38−/−Art2−/− mice, and observed a CD38-dependent, but ART2-independent, pristane-induced ISG expres-
sion profile (Fig. S4). To determine whether we could discriminate the groups of mice based on their ISG 
expression profile, unsupervised hierarchical clustering of gene expression was performed. We identified two 
distinct groups, clusters P and N, which clearly distinguished between pristane-treated and non-treated mice, 
respectively (Fig. 4a). Gene expression was grouped into 2 major clusters, A and B (Fig. 4a). Cluster A com-
prised of the 3 chemokine genes, namely Ccl7, Ccl2 and Ccl12, which showed the major differences in expres-
sion between pristane-treated and non-treated mice, while cluster B included the ISGs (Irf7, Isg15, and Mx1) 
as well as Tlr9, Ccr2 and Tlr7 that were differently distributed in subclusters. We used Principal Component 
analysis (PCA), a multivariate statistical approach, to confirm and select the best candidate genes for distin-
guishing pristane-treated from non-treated groups of mice. Figure 4b shows a score plot of the distribution of 
40 mice according to the expression variance of the 9 genes tested. Pristane-treated Art2−/− mice clustered in 
the upper left quadrant together with pristane-treated WT mice, indicating limited variance between these two 
groups of mice. The pristane-treated Cd38−/−Art2−/− double knockout mice clustered exclusively in the lower 
left quadrant, while the pristane-treated Cd38−/− mice clustered in the two lower quadrants in an intermediate 
area located between pristane-treated mice to the left and non-treated mice to the right. The non-treated WT 
Figure 4. Distinct clustering of mice according to the expression of Type I IFN-inducible genes in pristane-
treated vs. non-treated PECs. (a) Heat-map analysis of 9 genes, namely Ccr2, Tlr7, Tlr9, Isg15, Mx1, Irf7, Ccl7, 
Ccl12 and Ccl12, whose expression was useful in discriminating 2-weeks pristane-treated (cluster P) from 
control non-treated WT mice (cluster N). Gene expression profiles were separated into 2 major clusters (A and 
B), and each of them was further sub-dived into minor clusters according to expression pattern. (b) Principal 
Component Analysis (PCA) on the 9 selected genes showing a distinct expression profile in 2-weeks pristane-
treated vs. control non-treated mice. The score plot shows a spot map of the 40 mice tested (black circles: 
pristane-treated WT; black squares: non-treated WT; open circles: pristane-treated Cd38−/−; open squares: non-
treated Cd38−/−; red circles: pristane-treated Art2−/−; red squares: non-treated Art2−/−; blue circles: pristane-
treated Cd38−/−Art2−/−; blue squares: non-treated Cd38−/−Art2−/−) projected onto the first two principal 
components. The drawing lines highlight the clustering of mice of the same genetic background in distinct 
subareas according to their distinct gene expression profile in response to pristane treatment. (c) Loading 
plot of the 9 selected genes with expression levels projected onto the first two principal components. The plot 
shows that the genes clustered in distinct quadrants according to their differential expression in the 8 groups of 
experimental mice tested. (d–f) Heat-map analyses of gene expression in PECs (d) BM cells (e) and spleen cells 
(f) from 16-weeks pristane-treated WT and Cd38−/− mice compared to their non-treated WT counterpart.
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and Cd38−/− mice clustered in the upper right panel (black and open squares, respectively), while most of the 
non-treated Art2−/− mice, and all of the non-treated Cd38−/− Art2−/− double knockout mice clustered in the 
lower right panel (red and blue squares, respectively). In summary, mice clustered in different subareas depend-
ing on whether they were treated with pristane and whether they differed in CD38 expression. We generated a 
gene loading plot to cluster each individual gene in an attempt to identify strain-specific gene expression profiles 
that could be used to distinguish the groups of mice analysed (Fig. 4c). The expression of chemokines Ccl2 and 
Ccl12, which clustered in the upper left quadrant, associated with pristane-treated WT and Art2−/− mice, while 
the expression of chemokine Ccl7, which clustered in the lower left quadrant, associated with pristane-treated 
Cd38−/− and Cd38−/−Art2−/− mice. The expression of the other genes tested, namely Irf7, Isg15, Mx1, Tlr9, Ccr2 
and Tlr7, clustered in the right quadrants and therefore associated with the non-treated groups of mice. The sim-
ilar clustering into the upper right quadrant of non-treated WT and Cd38−/− mice (score plot in Fig. 4b) and the 
Tlr7, Tlr9, and Mx1 genes (loading plot in Fig. 4c) suggests that the expression profile of these genes could be used 
to discriminate non-treated WT and Cd38−/− mice from the other groups of mice analysed.
Expression of ISGs and TNF-α-regulated genes in splenic cells discriminate between 16-weeks 
pristane-treated Cd38−/− and WT mice. We also performed unsupervised hierarchical clustering of 
gene expression in PECs, BM, and splenic cells from 16-weeks pristane-treated WT and Cd38−/− mice. Since i.p. 
injection of pristane induces BM abnormalities and suppresses BM Cxcl12 mRNA expression by a TLR7-driven 
and TNF-α-mediated mechanism, which is IFN-I-independent29, we included gene expression analyses of Tnfα, 
Cxcl12 and the CXCL12 receptor Cxcr4. Despite the expected pristane-elicited decreased expression of Cxcl12 
and increased expression of Tnfα in WT BM cells, no differences were observed in the expression of these genes 
between pristane-elicited WT and Cd38−/− BM cells (Fig. S5), with the exception of Cxcr4 that was overexpressed, 
and Ccl12 and Irf7 that were underexpressed in Cd38−/− BM cells (Fig. S5).
Unsupervised hierarchical clustering of gene expression in PECs, BM and splenic cells from 16-weeks 
pristane-treated WT and Cd38−/− mice identified distinct clusters of non-treated and pristane-treated mice 
(Fig. 4d–f). Interestingly, pristane-elicited splenic cells could be separated into 2 subclusters, one consisting 
exclusively of WT mice, and the other mostly of Cd38−/− mice (Fig. 4f). Conversely, no clear separation could be 
achieved between pristane-elicited WT and Cd38−/− PECs (Fig. 4d) and BM cells (Fig. 4e). These results suggest 
that the differences in gene expression profiles between pristane-treated WT and Cd38−/− mice shifted from the 
PC and the BM at the 2-weeks time point to secondary lymphoid tissues, such as the spleen, by the 16-weeks time 
point.
Decreased CCL2 and IL-1α protein levels in the peritoneal lavage fluid of pristane-treated 
Cd38−/− mice. We measured the protein levels of the IFN-I-inducible chemokine CCL2 in the peritoneal 
lavage fluid, and found them to be significantly lower in 2-weeks pristane-treated Cd38−/− mice compared to WT 
mice (Fig. 5a). Moreover, the concentration of IL-1α, which is involved in neutrophil recruitment30, was signif-
icantly diminished in Cd38−/− mice (Fig. 5b). In contrast, the protein levels of the pro-inflammatory cytokine 
IL-6 were similar in both mice (Fig. 5c), while those of TNF-α and IL-12 were undetectable (data not shown). 
Next, we analysed the expression of CCR2, which is the major receptor for chemokines CCL2, CCL7 and CCL12, 
in different PEC populations from 2-weeks pristane-treated WT and Cd38−/− mice (Fig. S6). The number of 
CCR2hiLy6Chi monocytes was significantly lower in Cd38−/− mice compared to WT mice, while the number of 
CCR2+Ly6G+ neutrophils and CCR2+Ly6Clo monocytes were similar between the two groups of mice (Fig. S6). 
Indeed, these results are in agreement with the lower levels of CCL2 detected in the peritoneal lavage fluid from 
pristane-treated Cd38−/− mice (Fig. 5a).
Defective secretion of CCL2 and TNF-α by pristane-elicited PECs from Cd38−/− mice following 
TLR7 agonist stimulation. We next assessed the functional capacity of pristane-elicited PECs to respond 
to several TLR agonists. PECs from 2-weeks pristane-treated Cd38−/− mice produced significantly less CCL2 
in response to in vitro stimulation with LPS (TLR4 agonist), R848 (TLR7 agonist), or ODN1585 (TLR9 ago-
nist) (Fig. 5d). Interestingly, non-stimulated control Cd38−/− PECs showed decreased secretion of CCL2 as well 
(Fig. 5d). Similarly, Cd38−/− PECs produced less TNF-α in response to R848 compared to WT PECs (Fig. 5e). 
In contrast, no differences in the secretion of IL-6 and IL12(p70) were observed between WT and Cd38−/− PECs 
in response to these stimuli (Figs 5f and 6g, respectively). To determine whether the impaired TLR-mediated 
secretion of CCL2 and TNF-α by Cd38−/− PECs was due to intrinsic TLR signalling defects, we sorted perito-
neal Ly6Chi monocytes, Ly6Clo monocytes/macrophages and Ly6G+ neutrophils from 2-weeks pristane-treated 
WT and Cd38−/− mice and assessed their gene expression profiles. The sorting strategy used to purify these cell 
populations is shown in Fig. S7. Gene expression analyses (Fig. S8) and in vitro TLR agonist stimulations (data 
not shown) revealed no major intrinsic TLR signalling defects in Cd38−/− Ly6Chi monocytes, Ly6Clo monocytes/
macrophages and Ly6G+ neutrophils. Interestingly, Ccl2 gene expression was significantly upregulated in Cd38−/− 
Ly6Chi monocytes, indicative of a transcriptional effort by these cells to compensate for their impaired CCL2 
protein secretion.
CD38 deficiency does not impair M-CSF-induced differentiation of BM cells into anti- 
inflammatory macrophages. Increased Cd38 gene expression has been reported in human 
anti-inf lammatory M-CSF-dependent macrophages (M-MØ) compared to pro-inflammatory 
GM-CSF-dependent macrophages (GM-MØ)31 (Gene Expression Ommnibus reference: GSE68061). To assess 
whether the absence of CD38 affected the polarization of BM-derived macrophages, we isolated BM cells from 
Cd38−/− and WT naïve mice and differentiated them in vitro into anti-inflammatory macrophages as previ-
ously described32. Subsequent analysis of the mouse M-MØ-specific gene markers Emr1, Cd163, Cnrp1, and 
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Ctla2, and the GM-MØ-specific gene markers Nos2, Ccr7, and Cd11c revealed that there were no significant 
differences in the expression of these genes between Cd38−/− and WT cells (Fig. 5h), suggesting that CD38 does 
not play a role in the polarization of BM macrophages towards an anti-inflammatory phenotype. Interestingly, 
M-CSF-stimulated Cd38−/− BM cells manifested enhanced expansion compared to WT cells, as evidenced by 
the greater number of recovered cells after 7 days in culture (1.85-fold increase, data not shown). Whether CD38 
modulates M-CSF-induced proliferation of BM cells33,34 requires further investigation.
Defective recruitment of TNF-α-producing Ly6G+ neutrophils and Ly6Chi monocytes to the 
peritoneum of pristane-treated Cd38−/− mice. To further assess TNF-α production in Cd38−/− mice, 
we harvested PECs from mice at 1-, 2-, and 4-weeks post-pristane treatment and cultured them in vitro with 
Brefeldin A to inhibit protein transport and enhance intracellular TNF-α staining for flow cytometric detection. 
TNF-α was produced almost exclusively by CD11b+ cells, specifically by Ly6G− Ly6C+ monocytes and by Ly6C− 
Ly6G+ granulocytes (Fig. 6a). Two subpopulations of Ly6G+ cells were characterised based on granularity, despite 
differences in SSC properties between fixed/permeabilised and non-manipulated cells that made the nature of the 
subpopulations uncertain. However, since neutrophils are the most abundant granulocytes in pristane-treated 
mice, and eosinophils are Ly6Gint-negSSChi granulocytes35, we designated Ly6G+SSClo and Ly6GloSSChi cells as 
neutrophils and eosinophils, respectively (Fig. 6a). In agreement with previously published reports, we observed 
Figure 5. Defective pro-inflammatory phenotype of Cd38−/− PECs but not BM-derived macrophages. (a–c) 
Decreased in vivo secretion of CCL2 and IL-1α in pristane-treated Cd38−/− mice. Concentration of CCL2 
(a), IL-1α (b) and IL-6 (c) proteins (pg/ml) in the peritoneal lavage fluid of 2-weeks pristane-treated WT 
and Cd38−/− mice. Data are shown as the mean ± SE and represent cumulative data from 3 independent 
experiments (n = 15–22/group). *P < 0.05 ****P < 0.0001 by the Mann Whitney test. (d–g) Decreased in vitro 
secretion of CCL2 and TNF-α by pristane-elicited Cd38−/− PECs in in response to the TLR7 agonist R848. 
Concentration of CCL2 (d), TNF-α (e), IL-6 (f), and IL-12(p70) (g) proteins (pg/ml) in the supernatants of 
2-weeks pristane-elicited PECs from WT and Cd38−/− mice (5 mice/group) stimulated in vitro for 24 hours at 
37 °C and 5% CO2 with LPS, R848 or ODN1585. Each condition was tested in triplicate wells. Data are shown as 
the mean ± SE. *P < 0.05 **P < 0.01 ***P < 0.001 by 2-way ANOVA with Bonferroni’s multiple comparisons 
test. (h) Normal M-CSF-induced differentiation of Cd38−/− BM cells into anti-inflammatory macrophages. 
BM cells were isolated from naïve WT and Cd38−/− mice and differentiated in vitro into anti-inflammatory 
macrophages (M-MØ) by culturing them for 7 days in the presence of murine M-CSF as described in 
Methods. Gene expression of mouse M-MØ-specific gene markers Emr1, Cd163, Cnrp1, and Ctla2b, and pro-
inflammatory macrophage (GM-MØ)-specific gene markers Nos2, Ccr7, and Cd11c was measured by Q-PCR.
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Figure 6. Defective recruitment of TNF-α-producing neutrophils and Ly6Chi monocytes to the peritoneum of 
pristane-treated Cd38−/− mice. (a) Flow cytometric analyses of 4-weeks pristane-elicited PECs from WT and 
Cd38−/− mice first surface-stained with anti-CD11b, anti-Ly6G and anti-Ly6C fluorescent-labelled antibodies, 
and then intracellularly stained for TNF-α as described in Methods. The three CD11b+ peritoneal cell populations 
of interest were identified based on their level of Ly6G expression and side scatter (SSC) characteristics. The cell 
types were SSCloLy6G+ granulocytes (neutrophils), and SSChiLy6Glo granulocytes (eosinophils) and SSCloLy6G− 
monocytes. Each cell type was stimulated with PMA, ionomycin and Brefeldin A (BFA). As a control, each WT cell 
type was incubated with PMA and ionomycin alone. The level of TNF-α expression in each cell type is shown, and 
the representative frequencies are included in each gate. (b–e) Numbers of TNF-α+ Ly6Chi monocytes (b), TNF-α+ 
Ly6Clo monocytes (c), TNF-α+ Ly6G+ granulocytes/neutrophils (d), and TNFα+ Ly6Glo granulocytes/eosinophils 
(e) at 1-, 2- and 4-weeks post pristane treatment. Data are shown as the mean ± SE (n = 6–7 mice/group). All P values 
were determined by 2-way ANOVA with the Sidak’s multiple comparisons test. *P < 0.05 **P < 0.01 ***P < 0.001.
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an increase in the number of pristane-elicited TNF-α+Ly6G+ neutrophils in WT mice over time29,36, which out-
numbered the other cell types analysed (Fig. 6d). Importantly, at 4-weeks post-pristane treatment, which is the 
peak of the acute inflammatory response, Cd38−/− mice had decreased numbers of TNF-α+Ly6Chi monocytes 
(Fig. 6b), Ly6G+ neutrophils (Fig. 6d) and Ly6Glo eosinophils (Fig. 6e) compared to WT mice. No differences 
were observed in the number of TNF-α+Ly6Clo monocytes between Cd38−/− and WT mice (Fig. 6c).
To investigate whether the defective recruitment of TNF-α-producing Ly6G+ neutrophils and Ly6Chi mono-
cytes to the peritoneum of pristane-treated Cd38−/− mice was due to intrinsic chemotactic defects, we assessed 
the chemotaxis of mouse BM monocytes to CCL2 and CXCL12 in vitro (Fig. S9a,b) and the migration of Ly6G+ 
neutrophils to the peritoneum in response to in vivo zymosan challenge (Fig. S9c,d). Similar responses between 
WT and Cd38−/− mice were observed, suggesting that the migration of these cells in response to pristane was 
CD38-independent.
Decreased autoantibody production and renal inflammation in Cd38−/− mice. Pristane does not 
induce IgG anti-dsDNA antibodies in B6 mice, however it induces anti-ssDNA antibodies37. Hence, we tested 
anti-ssDNA antibodies at 12- and 16-weeks post-pristane treatment to determine whether lack of CD38 was 
protective. WT mice exhibited a significant increase in IgG anti-ssDNA antibody serum levels at 16-weeks com-
pared to 12-weeks post-pristane (median values: 26.3 U/ml at 16-weeks vs. 10.0 U/ml at 12-weeks, P = 0.0082, 
Mann Whitney test, n = 14) (Fig. 7a). Cd38−/− mice, on the other hand, had no differences between the two time 
points (median values: 24.9 U/ml at 16-weeks vs. 17.6 U/ml at 12-weeks, P = 0.1387, Mann Whitney test, n = 9). 
Furthermore, significantly fewer pristane-treated Cd38−/− mice (11%, n = 9) were positive for anti-nRNP autoan-
tibodies compared to WT mice (21%, n = 14) (Fig. 7b). The frequency of anti-nRNP antibodies we observed 
in pristane-treated WT mice was consistent with previously published values (24% of pristane-treated female 
B6 mice)28. In both Cd38−/− and WT mice, the serum levels of total IgG were lower at 16-weeks compared to 
12-weeks post-pristane treatment (Fig. 7c).
We next examined the effect of CD38 deficiency on the induction of lupus nephritis by evaluating glomerular 
cellularity at 12- and 16-weeks post-pristane treatment. Pristane-treated WT mice had increased glomerular 
cellularity compared to saline-treated control mice at both time points analyzed (Fig. 7d and e). Pristane-treated 
Cd38−/− mice, on the other hand, showed no statistically-significant difference in glomerular cellularity compared 
to saline-treated Cd38−/− control mice. The normal/background range of glomerular cellularity was calculated 
by analysing each individual saline-treated WT mouse, and found to be 71.4-32.7 (mean ± 2 SD of the number of 
nuclei/glomerulus). The percentage of WT mice with glomerular cellularity above the background 71.4 value was 
significantly higher at 16-weeks compared to 12-weeks post-pristane (40% vs. 28.6%), whereas the percentages of 
Cd38−/− mice remained constant at 13-14% (Fig. 7f and g). Therefore, the relatively mild renal disease induced by 
pristane in B6 WT mice37 was attenuated in Cd38−/− mice.
Discussion
CD38 deficiency results in decreased accumulation of Ly6Chi monocytes, Ly6Clo monocytes/macrophages and 
Ly6G+ neutrophils, and attenuated inflammation at 2- and 4-weeks post pristane treatment. Overall, our results 
imply that CD38 contributes to the development of pristane-induced lupus, particularly during the inflammatory 
phase prior to the onset of the autoimmune phase of the disease, which occurs 12–16 weeks post treatment. This 
is consistent with other models of inflammatory disorders in which Cd38−/− mice show only mild disease mani-
festations, namely CIA21, focal cerebral ischemia38, allergen-induced airway hyperresponsiveness39 and intestinal 
inflammation/colitis40. In these models, attenuated inflammation results from reduced production of cytokines 
and chemokines, as well as reduced migration of inflammatory cells. In this study, the attenuation of inflamma-
tion in Cd38−/− mice occurred at the peak of the inflammatory phase (2–4 weeks). Interestingly, during the early 
inflammatory phase (1-week), no attenuation was observed in the initial recruitment of Ly6Chi monocytes and 
Ly6G+ neutrophils to the peritoneum, and there was no defective production of pro-inflammatory cytokines/
chemokines required for the recruitment of these cells to the peritoneum (data not shown). Furthermore, there 
was no impairment of the in vitro chemotactic response of Cd38−/− BM-derived Ly6Chi monocytes to CCL2 and 
CXCL12, or the in vivo migratory capacity of Ly6G+ neutrophils to respond to an acute zymosan challenge in 
Cd38−/− mice. These data suggest that there is no intrinsic defect in the migration of these Cd38−/− cells from the 
BM to the peritoneum in response to pristane.
Pristane arrests cell growth in murine peritoneal cells and induces cell death by apoptosis via the mitochon-
drial pathway of caspase activation41. Pyroptosis, defined as caspase-1-dependent cell death following inflam-
masome activation, is also operative in pristane-treated mice42. Our data show that injection of pristane into the 
peritoneum induces apoptosis-mediated cell death of PECs, as evidenced by the increased number of annexin 
V+ peritoneal cells and their increased levels of cleaved/active caspase-3. Indeed, the higher levels of activated 
caspase-3 protein in WT PECs, particularly at 2-weeks post pristane treatment, are indicative of a higher rate 
of apoptosis compared to Cd38−/− cells. In contrast, no differences were observed in the levels of MCL-1, an 
anti-apoptotic protein and member of the BCL2 family43. Furthermore, kinases ERK1/2 and AKT showed dis-
tinct activation kinetics in pristane-elicited PECs. While caspase-3 activation followed similar kinetics to AKT 
activation in both WT and Cd38−/− PECs, ERK activation correlated with increased levels of MCL-1. MCL-1 is 
crucial for the survival of neutrophils, and there are many signalling pathways that contribute to its stabilization 
and expression, including AKT, ERK and agonists of TLR4, TLR7 and TLR9, either via direct phosphorylation 
or indirectly via NF-κB activation44. The persistent activation of ERK in WT PECs, which was not observed in 
Cd38−/− PECs, may also account for the stronger pro-inflammatory response of WT PECs to pristane challenge. 
Recent studies have shown that in addition to its role as a survival factor and tumor promoting agent, AKT is 
also able to exhibit pro-apoptotic effects under diverse conditions, including oxidative stress45–47, cytokine stim-
ulation48,49 and exposure to cytotoxic chemicals like staurosporine, methotrexate, docetaxel and etoposide49,50. 
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Figure 7. Diminished autoantibody production and attenuated glomerulonephritis in pristane-treated Cd38−/− 
mice. (a) IgG anti-single-stranded DNA (ssDNA) autoantibody serum levels in Cd38−/− mice (n = 9) and WT 
control mice (n = 14) at 12- and 16-weeks post pristane treatment. Dashed line indicates the concentration (U/
ml) of anti-ssDNA antibodies above which the anti-ssDNA levels were considered statistically significant. (b) 
Anti-nRNP autoantibody levels in non-treated and 16-weeks pristane-treated Cd38−/− and WT mice. Dashed 
line indicates the normalized value of anti-nRNP antibody levels calculated as described in Methods. (c) 
Serum levels of total IgG (mg/ml) in 12- and 16-weeks pristane-treated Cd38−/− and WT mice. Horizontal bars 
represent the mean value for each group. (d) H&E stained sections of kidneys from WT and Cd38−/− mice 12-
weeks post PBS or pristane treatment, and 16-weeks post pristane treatment. Original magnification × 100. In 
each panel horizontal bars indicate the distance in μm. (e) Cumulative data of glomerular cell numbers in WT 
(n = 3) and Cd38−/− (n = 5) mice 12-weeks post PBS treatment, WT (n = 7) and Cd38−/− (n = 8) mice  
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Moreover, phosphorylation of second mitochondria-derived activator of caspases (SMAC) by AKT promotes 
caspase-3 activation during etoposide-induced apoptosis in HeLa cells51. Our data are in agreement with these 
studies, and demonstrate that in some instances AKT activation is associated with apoptotic signals and not with 
survival signals. Further studies, however, are required to identify specific pro- and anti-apoptotic target proteins 
that are phosphorylated by ERK or AKT following pristane treatment, and that regulate the apoptotic process.
There is evidence that enzymatic activity of CD38 is important for regulating apoptosis of immune cells. 
NAD is converted by CD38 into ADPR that can bind to and activate the Ca2+-permeable channel TRPM252. 
CD38 also produces other TRPM2 regulators, namely cADPR and NAADP, which can synergize with ADPR 
to potentiate TRPM2 activation10. TRPM2 is highly expressed in phagocytes and since the influx of Ca2+ 
through TRPM2 results in activation of extrinsic and intrinsic cell death pathways10,53–56 it is probable that 
the NAD-ADPR-TRPM2 pathway participates in the regulation of pristane-induced apoptosis. We show that 
pristane-induced apoptosis is similarly defective in Trpm2−/− and Cd38−/− Ly6Chi monocytes. This suggests that 
CD38- and ADPR/TRPM2-mediated calcium signalling plays an important role in pristane-induced apoptosis 
of peritoneal monocytes. ADPR can be generated either by the interplay between poly(ADP-ribose) polymerases 
(PARPs) and their catabolic counterpart poly(ADP-ribose) glycohydrolase (PARG)57,58 or by CD3859,60. CD38 is 
generally thought of as a type II membrane-bound ectoenzyme, with its catalytic site in the extracellular space61 
but recent evidence is making the case for a type III orientation in which the active site of an enzymatically active 
CD38 is facing the cytoplasm62,63. Hence, in light of these findings, ADPR production by CD38 does not seem 
to be limited to the extracellular space. Interestingly, a new TRPM2 superagonist, namely 2′-deoxy-ADPR, was 
recently identified in Jurkat T cells as an intracellular product of type III CD38 and found to be more potent than 
ADPR at inducing TRPM2-mediated whole-cell currents64. Moreover, intracellular production of ADPR by CD38 
was reported in NK cells and shown to modulate Ca2+ signalling by gating TRPM2 channels and contributing 
to the anti-tumor activity of NK cells65. Hence, we propose that in the presence of CD38, the abnormally high 
concentration of intracelular NAD resulting from chronic inflammation is converted into ADPR, which induces 
enhanced and persistent TRPM2-mediated Ca2+ influx that may tilt the balance towards cell death. In Cd38−/− 
mice, the increased concentration of intracellular NAD would stimulate the deacetylase activity of SIRT1 (and 
other sirtuins) while the low production of ADPR would attenuate TRMP2 channel activity. Both effects are likely 
to have an impact on the inflammatory and autoimmune processes triggered by pristane. Hence, pharmacological 
inhibition of CD38 activity or treatment with anti-CD38 antibodies could prevent some of the pristane-induced 
effects in WT mice. Interestingly, this mechanism does not seem to be operative in neutrophils, since no dif-
ferences in frequencies and numbers of early-apoptotic pristane-elicited Ly6G+ neutrophils were detected in 
Cd38−/− and Trpm2−/− mice at 1- and 2-weeks post pristane treatment. One possible explanation for these results 
may be the more potent pro-inflammatory peritoneal environment in WT mice. Increased TNF-α production, 
which is significantly more pronounced in neutrophils, may stimulate ERK activation and decrease MCL-1 deg-
radation in these cells and not in monocytes. Indeed, this is a well-established neutrophilic mechanism of pro-
tection from apoptosis44.
Apoptosis does not normally activate the immune system since apoptotic cells are rapidly cleared by phago-
cytes without the release of nucleosomes and with minimal inflammation66. However, inefficient clearance of 
dying cells can result in the accumulation of apoptotic cell remnants and lead to a process referred to as sec-
ondary necrosis67. Secondary necrosis can result in a permanent presence of cellular debris that can initiate 
pristane-induced lupus2,41 and systemic autoimmunity in SLE67. The pro-apoptotic effect of CD38 and TRPM2 
expression in Ly6Chi monocytes is particularly harmful in the pristane-induced model of lupus in which PECs lack 
highly phagocytic resident peritoneal macrophages (Tim4+ macs), and have low numbers of anti-inflammatory 
elicited macrophages (Tim4−CD138+Marco+ macs), which have increased phagocytic capacity for apoptotic cell 
clearance compared to Tim4+ macs68. Macrophages are the primary cell type responsible for the resolution of 
inflammation and the clearance of apoptotic debris in most tissues. Phagocytosis of apoptotic neutrophils by 
macrophages promotes a switch from a pro- to an anti-inflammatory macrophage phenotype69, which is clearly 
delayed or absent in pristane-induced lupus and other animal models of lupus70. In Cd38−/− and Trpm2−/− mice, 
the decreased pristane-induced apoptosis of Ly6Chi monocytes may allow for a more effective clearance of apop-
totic bodies and potentially harmful material compared to WT mice.
Interestingly, apoptotic cell engulfment activates nuclear receptors, such as Liver X receptors (LXR), which in 
turn induce the expression of the receptor tyrosine kinase Mer that is critical for phagocytosis71. In macrophages, 
CD38 expression is required for the control of bacterial infection mediated by LXR through a mechanism that 
involves consumption of NAD72. Moreover, agonist activation of LXR induces the transcriptional activation of 
CD38 synergistically with pro-inflammatory cytokines/mediators, such as TNF-α, IFN-γ, and lipopolysaccha-
ride (LPS)72. Hence, it is possible that CD38 is required for other LXR-mediated activities beyond the control of 
infection.
Decreased clearance of apoptotic cells is a mechanism prevalent in lupus-prone mice70. While activation of 
LXR improves the clearance of apoptotic cells and ameliorates progression in lupus-prone B6lpr/lpr mice, the lack 
of LXR leads to age-dependent systemic autoimmune disease71. Importantly, CD38 deficiency contributes to the 
12-weeks post pristane treatment, and WT (n = 5) and Cd38−/− (n = 7) mice 16-weeks post pristane treatment. 
Glomerular cellularity was evaluated by counting the number of nuclei per glomerular cross-section (8 
glomeruli/mouse). *P < 0.05 **P < 0.01 by 2-way ANOVA with Bonferroni’s multiple comparisons test. (f,g) 
Glomerular cellularity of each individual mouse at 12-weeks (f) and 16-weeks (g) post pristane treatment. 
Dashed lines represent the mean value for the number of nuclei per glomerulus in PBS-treated WT mice, and 
the dotted lines represent the upper and lower limits of normality (mean ± 2 SD).
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exacerbation of the lupus-like disease in B6lpr/lpr mice73, with clinical and immunological abnormalities resem-
bling those in LXR-deficient mice71. Although the underlying mechanism has not yet been fully investigated, we 
speculate that the lack of CD38 in B6lpr/lpr mice may affect the activation of LXR resulting in decreased clearance 
of apoptotic cells. We further speculate that in the peritoneum of pristane-treated WT mice, CD38-mediated 
LXR activation may be impaired due to the low number of peritoneal macrophages present. Therefore, WT mice 
would have to cope with a massive rate of apoptosis accompanied by defective clearance of apoptotic remnants. 
In Cd38−/− mice, on the other hand, the lower number of apoptotic Ly6Chi monocytes may allow for more effec-
tive clearance of apoptotic bodies and potentially harmful material despite a malfunctioning CD38-LXR axis72. 
Therefore, the pristane-elicited unbalanced cell environment in the peritoneum is crucial to the outcome of the 
lupus disease.
NAD-induced cell death (NICD), which acts through the ART2-P2X7 pathway74,75 is regulated by CD38. 
Indeed, lack of CD38 in ART2+ T cells results in increased NICD, which correlates with a significant reduc-
tion in Tregs and iNKT cells, even under steady-state conditions76. Moreover, CD38 deficiency accelerates dia-
betes type I (T1D) in NOD mice via a drastic reduction in regulatory CD4+ iNKT cells, which greatly affects 
the iNKT-mediated induction of tolerogenic dendritic cells (DCs) in specific niches, such as pancreatic lymph 
nodes77. Indeed, the loss of peripheral CD4+ iNKT cells in Cd38−/− mice is due to ART2-dependent NICD77. In 
mice with a B6 genetic background, on the other hand, activated iNKT cells can boost a Th1 response by inducing 
the differentiation of DCs to an immunogenic or pro-inflammatory phenotype that support, rather than inhibit, 
AI4 T-cell-induced T1D78. Therefore, iNKT cells can play both suppressive and pathogenic roles in the regulation 
of T1D, in a genetically-determined manner. We have reported a similar mechanism in the pathogenesis of CIA, 
and showed that lack of CD38 in a B6 genetic background ameliorated the disease due to decreased iNKT cells in 
secondary lymphoid organs that were unable to boost a Th1 response21.
The concentration of extracellular NAD in the peritoneum may increase significantly in pristane-treated mice 
as a consequence of the high number of apoptotic cells. NAD may diffuse and reach local draining lymph nodes, 
or the tertiary lymphoid tissues, known as lipogranulomes, that are formed in response to pristane79. Hence, 
extracellular NAD may induce measurable ART2-dependent effects on the phenotype or function of T cells in 
these compartments76, a hypothesis that was not tested in this study. The mechanisms of apoptosis that induce a 
defective number of Ly6Chi monocytes in Cd38−/− PECs upon pristane treatment seem to be CD38-dependent 
and ART2-independent. Moreover, deficiency of CD38, but not of ART2, alters the pristane-elicited expression 
of ISGs. Regarding glomerular cellularity, 12-weeks pristane-treated Art2−/− mice showed an increased response 
similar to their WT counterparts, while Cd38−/−Art2−/− double knockout mice exhibited a decreased response 
similar to Cd38−/− mice (data not shown). Therefore, ART2 deficiency does not seem to affect the development 
of pristane-induced lupus.
In summary, CD38 enhances the development of pristane-induced lupus by regulating the cell death of Ly6Chi 
monocytes and Ly6Clo monocytes/macrophages in a TRPM2-dependent and ART2-independent manner that 
worsens the early inflammatory response in the peritoneum. Our results highlight the importance of the immu-
noregulatory role of CD38 in inflammation and in the development of systemic autoimmunity leading to lupus, 
which should be considered when designing CD38-specific therapies for the treatment of inflammatory and 
autoimmune diseases.
Methods
Mice and pristane treatment. Cd38−/−, Art2−/−, and Cd38−/−Art2−/− double knockout mice were 
backcrossed for 12 generations to the C57BL/6 J (B6) background80–82, bred and maintained under specific 
pathogen-free conditions at the IPBLN-CSIC Animal Facility in Granada, Spain. ARTC2 is a toxin-related, GPI-
anchored ADP-ribosyltransferase expressed by murine T cells, also known as ART281,83. Please note that ART2 is 
encoded by two closely related tandem genes in the mouse designated Art2.1 and Art2.2. The ART2.1 and ART2.2 
gene products are co-expressed by T cells and show similar enzymatic activities. The Art2−/− mice are deficient 
for Art2.1 and Art2.281. For the sake of brevity “ART2” is used throughout this paper instead of “ART2.1 and 
ART2.2”. Wild-type C57BL/6 J mice were purchased from Charles River (Barcelona, Spain). Trpm2−/− mice were 
kindly provided by Dr. Yasuo Mori from Kyoto University, Japan, and the generation of this mouse strain has been 
described84. Experimental mice received a single dose of 0.5 ml pristane (2,6,10,14-tetramethylpentadecane1; 
Sigma-Aldrich) that was filtered through a 0.25-μm filter and administered intraperitoneally (i.p.). Control mice 
received either a single dose of 0.5 ml saline or were left untreated. All experimental procedures involving animals 
at IPBLN-CSIC were approved by the Institutional Animal Care and Use Committee, which follows the ARRIVE 
guidelines85 in accordance with the U.K. Animals (Scientific Procedures, Act, 1986) and associated guidelines (EU 
Directive 2010/63/EU for animal experiments), and with the National Institutes of Health guide for the care and 
use of Laboratory animals (NIH Publications No. 8023, revised 1978). All the experiments with WT, Cd38−/− and 
Trpm2−/− mice described in Figs 3, S1 and S2 were carried out at the University of Alabama at Birmingham in the 
laboratory of Dr. Frances E. Lund, approved by the Institutional Animal Care and Use Committee, and performed 
according to guidelines outlined by the National Research Council.
Flow cytometry and cell sorting. Flow cytometry analyses at IPBLN-CSIC were performed as previ-
ously described86. Before surface staining, peritoneal or peripheral blood cells were incubated with anti-mouse 
CD16/32 (Fc Block; BD Biosciences) for 10 min. Cells then were stained with an optimized amount of primary 
Ab or the appropriate isotype control for 10 min at room temperature before washing and re-suspending in stain-
ing media (PBS supplemented with 0.1% BSA and 2 mM EDTA). Ten thousand to 50,000 events per sample 
were acquired using a FACSCalibur flow cytometer (4-color, BD Biosciences) and analysed with FlowJo soft-
ware (Tree Star, Inc.). The following conjugated mAbs were used: B220-FITC, CXCR4-APC, and CD11b-FITC 
(BioLegend), CD11b-APC, MHC-PE, CD11c-FITC, and CD8α-APC (Miltenyi Biotec), Gr1-PE, CD5-PerCP, 
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Ly6C-PE, CD4-PerCP, Ly6C-FITC, and Ly6G-PE, Ly6G-PerCP (BD Biosciences). Unconjugated anti-mouse 
CCR2 mAb (clone MC-21) was used to detect surface expression of CCR287. Briefly, cells were incubated with 
5 μg/ml anti-mouse CCR2 mAb for 1 hour on ice, followed by 5 μg/ml biotinylated mouse anti-rat IgG2b (Clone 
RG7/11.1; BD Biosciences) for 30 min on ice. After blocking with 10% rat serum for 10 minutes, streptavidin-PE 
and a combination of directly labelled antibodies were added (CD11b-APC, Ly6C-FITC, and Ly6G-PerCP).
Cell sorting was performed using a FACSAria III flow cytometer (BD Biosciences). PECs from pools of 5 
mice/group (2-weeks pristane-treated mice) were stained with CD11b-APC, Ly6C-FITC and Ly6G-PE mAbs. 
Doublets (FSC-H vs. FSC-A) were excluded and CD11b+ cells were gated in the singlet population prior to sort-
ing. Ly6Chi monocytes (CD11b+Ly6G−Ly6Chi), Ly6Clo monocytes/macrophages (CD11b+Ly6G−Ly6Clo), and 
granulocytes (CD11b+Ly6G+Ly6Cint) were sorted to 92–99.8% purity for cell culture or RNA isolation.
Flow cytometry analyses at UAB were performed using a FACSCanto II (BD Biosciences) flow cytometer. 
Peritoneal cells were incubated in staining media for 20 min on ice with a surface staining mix consisting of 
Ly6G-PE (clone 1A8; 1:200), CD19-APC (clone 1D3; 1:200), Ly6C-APC-Cy7 (clone AL-21; 1:200), CD11b-V500 
(clone M1/70; 1:200) and Fc Block (1:1000) from BD Biosciences and CD3-Pacific Blue (Biolegend clone 17A2; 
1:200) from Biolegend. Cells were then washed with ice-cold PBS and stained for apoptotic/necrotic cells using 
the FITC Annexin V Apoptosis Detection kit I (BD Biosciences). Briefly, cells were incubated with Annexin 
V-FITC (1:50) and 7-AAD (1:1000) in 1 × Annexin V binding buffer on ice for 15 min. The stained PECs were 
then diluted 1:2 with 1 × Annexin V binding buffer prior to acquisition on the flow cytometer. Single-color con-
trols were generated by staining murine splenocytes with the following single mAbs in staining media on ice 
for 20 min: CD4-FITC (clone GK1.5; 1:200), CD4-PE (clone RM4-5; 1:200), CD8a-PerCP-Cy5.5 (clone 53-6.7; 
1:200), CD4-PE-Cy7 (clone RM4-5; 1:200), CD45R/B220-APC-Cy7 (clone RA3-6B2; 1:200), and CD4-V500 
(clone RM-4-5; 1:200) from BD Biosciences, and CD4-Pacific Blue (clone GK1.5; 1:200) and CD4-APC (clone 
RM4-5; 1:200) from BioLegend.
Intracellular cytokine staining. Intracellular TNF-α was detected after culturing pristane-elicited PECs in 
vitro for 1 hour at a concentration of 2.5 × 106 cells/ml in RPMI 1640 medium containing 10% fetal bovine serum 
(FBS), 20 ng/ml PMA and 1 μg/ml ionomycin, and stimulating them for 4 hours with 1 μg/ml Brefeldin A (BFA; 
Sigma-Aldrich) at 37 °C and 5% CO2. After stimulation, cells were surface stained, fixed and permeabilised using 
the Inside Stain Kit (Miltenyi Biotec), and stained with either TNF-α-FITC (Miltenyi Biotec) or isotype controls 
according to the manufacturer’s protocol for cells in suspension. Cells treated with PMA and ionomycin in the 
absence of BFA served as the negative controls. Cells were then washed twice in Perm/Wash buffer, resuspended 
in staining media, and analysed by flow cytometry.
Cytokine ELISAs. The Bio-Plex Precision Pro Mouse Cytokine 3-Plex kit assay (Bio-Rad Laboratories) was 
used to simultaneously test cytokines IL-6, IL-12(p70) and TNF-α, and chemokine CCL2 (MCP-1). All 14 mouse 
IFN-α subtypes were measured using the Verikine Mouse Interferon-alpha ELISA (PBL Assay Science). Assays 
were performed according to the manufacturers’ protocols. Analyses of experimental data were carried out using 
five-parameter logistic curve fitting to standard analyte values.
Chemotaxis assays. BM cells from WT and Cd38−/− naïve mice were first stained with biotinylated CD115 
antibody and MACS streptavidin microbeads (Miltenyi Biotec) and then positively selected on a MACS midi 
column. Purified monocytes were washed and re-suspended in HBSS (Ca2+, Mg2+) supplemented with 1% FBS. 
Chemotaxis assays were performed in 24-well Transwell plates (Costar, Cambridge, MA) with 5-μm pore size 
polycarbonate filters as previously described7. Briefly, CCL2 or CXCL12 chemokines were diluted in HBSS, and 
placed in the lower chamber of the Transwell while cells were added to the upper chamber. For mouse monocyte 
assays, 5 × 105 cells/Transwell were incubated at 37 °C for 2 hours. The transmigrated cells were collected from the 
lower chamber, fixed, and counted on a flow cytometer.
Western-blotting experiments. 1% NP-40 lysates from 2-, 4- and 8-weeks pristane-elicited PECs were 
run on Criterion TGX stain-free gels (Bio-Rad Laboratories), and immediately after electrophoretic separation 
was complete, the gels were activated with UV-light using the Gel Doc EZ system (Bio-Rad Laboratories) and the 
proteins were transferred to PVDF membranes using the Trans-Blot Turbo system (Bio-Rad Laboratories). Once 
the blotting step was complete, a stain-free blot image of the PVDF membrane was acquired prior to blocking 
with 5% non-fat dry milk in tris (hydroxymethyl) aminomethane-buffered saline containing 0.1% polysorbate 
surfactant (TBST) for 1 hour at room temperature. The membranes were then incubated overnight at 4 °C with 
either a polyclonal rabbit antibody specific for the 17 kDa subunit of active caspase-3 (ImmunoStep, Salamanca, 
Spain), monoclonal antibodies specific for phospho-ERK1/2 (Thr185/Tyr187), total Erk1/2, phospho-AKT (Ser473) 
and total AKT (Cell Signaling Technology, Massachusetts), or a polyclonal antibody specific for MCL-1 (Santa 
Cruz Biotechnology). The membranes were washed several times with TBST and incubated with horseradish 
peroxidase-conjugated goat anti-rabbit or anti-mouse secondary antibodies (Cell Signaling Technology) accord-
ingly, for 1 hour. The blots were washed again and developed by chemiluminescence with substrate Immun-Star 
HRP substrate (Bio-Rad Laboratories) using a Chemidoc image analyzer (Bio-Rad Laboratories). The Stain-Free 
technology was used as a loading control method88.
Polarization of BM-derived macrophages. BM cells from Cd38−/− or WT naïve mice were differenti-
ated towards anti-inflammatory macrophages by culturing them for 7 days in the presence of murine M-CSF as 
previously described32. Subsequent analyses of the mouse M-Mφ-specific gene markers Emr1, Cd163, Cnrp1, and 
Ctla2, and the GM-Mφ-specific gene markers Nos2, Ccr7, and Cd11c were performed as previously described32.
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Serological studies. Serum levels of IgG anti-ssDNA autoantibodies were measured by ELISA, and the 
results were expressed in titration units (U/ml) extrapolated from a standard curve generated with a serial dilu-
tion of a serum pool from 6- to 8-month-old MRL-Faslpr mice as previously described89. Total IgG serum levels 
were measured by ELISA as previously described89,90. The mouse anti-nRNP total Ig ELISA kit (Alpha Diagnostic 
International) was used to quantify total nRNP-specific antibody (IgG, IgA, and IgM) in sera following the man-
ufacturer’s instructions. To quantify positive antibody levels, a Positive index was first determined by calculating 
the net OD mean + 3 SD of the Control/Non-immune samples. Each sample net OD was then divided by the 
Positive Index. A value above 1.0 was considered a Positive Antibody Activity, while a value below 1.0 was con-
sidered a Negative Antibody Activity.
Assessment of glomerulonephritis. Kidneys were excised from experimental and control mice, fixed in 
4% paraformaldehyde, and embedded in paraffin. Glomerular cellularity was evaluated by counting the number 
of nuclei per glomerular cross-section (n = 5 mice/group or as indicated, 8 glomeruli/mouse) after staining with 
hematoxylin and eosin (H&E)37. Nuclei number analysis was automated using the open-source ImageJ platform 
Fiji91.
Real-time quantitative PCR. Quantitative PCR (Q-PCR) was performed as previously described86. In 
brief, total RNA was extracted from 106 peritoneal cells using TRIzol reagent (Invitrogen), and cDNA was synthe-
sized using the Superscript II First-Strand Synthesis kit (Invitrogen) following the manufacturer’s protocol. SYBR 
Green Q-PCR analysis was performed using an Opticon II thermocycler (Bio-Rad Laboratories). Amplification 
conditions were as follows: 95 °C for 10 min, followed by 45 cycles of 94 °C for 15 s, 60 °C for 25 s, and 72 °C for 
25 s. After the final extension (72 °C for 10 min), a melting-curve analysis was performed to ensure specificity of 
the products. Primer sequences for Ccl2, Ccl7, Ccl12, Ccr2, Cxcl12, Cxcr4, Isg15, Irf7, Ly6G, Mx1, Tlr7, Tlr9, and 
Tnfα are listed in Supplemental Table S1.
Q-PCR data analysis. Cycle threshold (Ct) values were processed and normalized with R 3.2.2 (R-Core 
2015) using the comparative Ct method92 based on the comparison of the Ct values of the gene of interest nor-
malized to the Ct values of the housekeeping internal control genes. Following normalization, a quality step 
was performed to evaluate the replicate’s performance. Principal component analysis (PCA), heat-maps, clus-
ter dendrograms and boxplots of raw and normalized Ct values were assessed using the HTqPCR platform 
(Bioconductor)93.
Statistical analysis. To measure differential expression, limma package94 was used for statistical analysis 




−ΔΔ2 [(Ct gene of interest Ct internal control)sample A [(Ct gene of interest Ct internal control)
sample B]
Ct
Genes having a FDR lower than 0.05 were designated as differentially expressed. For other phenotypical and 
functional assays, statistical analyses were performed using the Prism 7 software (GraphPad).
References
 1. Satoh, M. & Reeves, W. H. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J 
Exp Med 180, 2341–2346 (1994). 
 2. Reeves, W. H., Lee, P. Y., Weinstein, J. S., Satoh, M. & Lu, L. Induction of autoimmunity by pristane and other naturally occurring 
hydrocarbons. Trends Immunol 30, 455–464, https://doi.org/10.1016/j.it.2009.06.003 (2009).
 3. Zhuang, H., Szeto, C., Han, S., Yang, L. & Reeves, W. H. Animal Models of Interferon Signature PositiveLupus. Frontiers in 
immunology 6, 291, https://doi.org/10.3389/fimmu.2015.00291, scisignal.257mr1 (2015).
 4. Quarona, V. et al. CD38 and CD157: A long journey from activation markers to multifunctional molecules. Cytometry B Clin Cytom 
84, 207–217, https://doi.org/10.1002/cyto.b.21092 (2013).
 5. Koch-Nolte, F., Haag, F., Guse, A. H., Lund, F. & Ziegler, M. Emerging roles of NAD+ and its metabolites in cell signaling. Sci Signal 
2, mr1, https://doi.org/10.1126/scisignal.257mr1 (2009).
 6. Lund, F. E. Signaling properties of CD38 in the mouse immune system: enzyme-dependent and -independent roles in immunity. 
Mol Med 12, 328–333 (2006).
 7. Partida-Sanchez, S. et al. Regulation of dendritic cell trafficking by the ADP-ribosyl cyclase CD38: impact on the development of 
humoral immunity. Immunity 20, 279–291 (2004).
 8. Partida-Sánchez, S. et al. Chemotaxis and Calcium Responses of Phagocytes to Formyl Peptide Receptor Ligands Is Differentially 
Regulated by Cyclic ADP Ribose. The Journal of Immunology 172, 1896–1906, https://doi.org/10.4049/jimmunol.172.3.1896 (2004).
 9. Lund, F. E. et al. CD38 induces apoptosis of a murine pro-B leukemic cell line by a tyrosine kinase-dependent but ADP-ribosyl 
cyclase- and NAD glycohydrolase-independent mechanism. Int Immunol 18, 1029–1042 (2006).
 10. Massullo, P., Sumoza-Toledo, A., Bhagat, H. & Partida-Sanchez, S. TRPM channels, calcium and redox sensors during innate 
immune responses. Semin Cell Dev Biol 17, 654–666, https://doi.org/10.1016/j.semcdb.2006.11.006 (2006).
 11. Partida-Sanchez, S. et al. Chemotaxis of mouse bone marrow neutrophils and dendritic cells is controlled by adp-ribose, the major 
product generated by the CD38 enzyme reaction. Journal of immunology 179, 7827–7839 (2007).
 12. Shi, G. et al. Identification of an alternative Gαq-dependent chemokine receptor signal transduction pathway in dendritic cells and 
granulocytes. The Journal of Experimental Medicine 204, 2705–2718, https://doi.org/10.1084/jem.20071267 (2007).
 13. Zubiaur, M., Izquierdo, M., Terhorst, C., Malavasi, F. & Sancho, J. CD38 ligation results in activation of the Raf-1/mitogen-activated 
protein kinase and the CD3-zeta/zeta-associated protein-70 signaling pathways in Jurkat T lymphocytes. Journal of immunology 
159, 193–205 (1997).
 14. Zumaquero, E. et al. Exosomes from human lymphoblastoid B cells express enzymatically active CD38 that is associated with 
signaling complexes containing CD81, Hsc-70 and Lyn. Exp Cell Res 316, 2692–2706, S0014-4827(10)00295-8, https://doi.
org/10.1016/j.yexcr.2010.05.032 (2010).
www.nature.com/scientificreports/
17SCIENTIFIC RepoRts |  (2018) 8:3357  | DOI:10.1038/s41598-018-21337-6
 15. Patton, D. T., Wilson, M. D., Rowan, W. C., Soond, D. R. & Okkenhaug, K. The PI3K p110delta regulates expression of CD38 on 
regulatory T cells. PLoS ONE 6, e17359, https://doi.org/10.1371/journal.pone.0017359 (2011).
 16. Blair, P. A. et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired 
in systemic Lupus Erythematosus patients. Immunity 32, 129–140, https://doi.org/10.1016/j.immuni.2009.11.009, S1074-
7613(09)00547-0 (2010).
 17. Munoz, P. et al. Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. 
Blood 111, 3653–3664 (2008).
 18. Malavasi, F. et al. CD38 and chronic lymphocytic leukemia: a decade later. Blood 118, 3470–3478, https://doi.org/10.1182/
blood-2011-06-275610, (2011).
 19. Pavon, E. J. et al. Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with 
distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Cytokine 62, 232–243, https://doi.
org/10.1016/j.cyto.2013.02.023 (2013).
 20. Bradley, S. J., Suarez-Fueyo, A., Moss, D. R., Kyttaris, V. C. & Tsokos, G. C. T Cell Transcriptomes Describe Patient Subtypes in 
Systemic Lupus Erythematosus. PLoS ONE 10, e0141171, https://doi.org/10.1371/journal.pone.0141171 (2015).
 21. Postigo, J. et al. Mice Deficient in CD38 Develop an Attenuated Form of Collagen Type II-Induced Arthritis. PLoS ONE 7, e33534, 
https://doi.org/10.1371/journal.pone.0033534 PONE-D-11-24323 (2012).
 22. Lee, P. Y. et al. A novel type I IFN-producing cell subset in murine lupus. Journal of immunology 180, 5101–5108 (2008).
 23. Lee, P. Y. et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp 
Med 205, 2995–3006, https://doi.org/10.1084/jem.20080462 (2008).
 24. Adriouch, S. et al. NAD+ released during inflammation participates in T cell homeostasis by inducing ART2-mediated death of 
naive T cells in vivo. Journal of immunology 179, 186–194, 179/1/186 (2007).
 25. Seman, M. et al. NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 
purinoceptor. Immunity 19, 571–582, S1074761303002668 (2003).
 26. Krebs, C. et al. CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins. Journal of 
immunology 174, 3298–3305 (2005).
 27. Yang, J. Q. et al. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. Journal of immunology 
171, 2142–2153 (2003).
 28. Satoh, M. et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clinical 
and experimental immunology 121, 399–405 (2000).
 29. Zhuang, H. et al. Toll-like receptor 7-stimulated tumor necrosis factor alpha causes bone marrow damage in systemic lupus 
erythematosus. Arthritis Rheumatol 66, 140–151, https://doi.org/10.1002/art.38189 (2014).
 30. Lee, P. Y. et al. IL-1alpha modulates neutrophil recruitment in chronic inflammation induced by hydrocarbon oil. Journal of 
immunology 186, 1747–1754, https://doi.org/10.4049/jimmunol.1001328 (2011).
 31. Gonzalez-Dominguez, E. et al. Atypical Activin A and IL-10 Production Impairs Human CD16+ Monocyte Differentiation into 
Anti-Inflammatory Macrophages. Journal of immunology 196, 1327–1337, https://doi.org/10.4049/jimmunol.1501177 (2016).
 32. Sierra-Filardi, E. et al. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent 
gene expression profile. Journal of immunology 192, 3858–3867, https://doi.org/10.4049/jimmunol.1302821 (2014).
 33. Fleetwood, A. J., Dinh, H., Cook, A. D., Hertzog, P. J. & Hamilton, J. A. GM-CSF- and M-CSF-dependent macrophage phenotypes 
display differential dependence on type I interferon signaling. J Leukoc Biol 86, 411–421, https://doi.org/10.1189/jlb.1108702 (2009).
 34. Lacey, D. C. et al. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. Journal of 
immunology 188, 5752–5765, https://doi.org/10.4049/jimmunol.1103426 (2012).
 35. Rose, S., Misharin, A. & Perlman, H. A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment. 
Cytometry Part A 81A, 343–350, https://doi.org/10.1002/cyto.a.22012 (2012).
 36. Xu, Y. et al. Mechanisms of tumor necrosis factor alpha antagonist-induced lupus in a murine model. Arthritis Rheumatol 67, 
225–237, https://doi.org/10.1002/art.38882 (2015).
 37. Xu, Y. et al. Pleiotropic IFN-dependent and -independent effects of IRF5 on the pathogenesis of experimental lupus. Journal of 
immunology 188, 4113–4121, https://doi.org/10.4049/jimmunol.1103113 (2012).
 38. Choe, C. U. et al. CD38 exacerbates focal cytokine production, postischemic inflammation and brain injury after focal cerebral 
ischemia. PLoS ONE 6, e19046, https://doi.org/10.1371/journal.pone.0019046 (2011).
 39. Gally, F., Hartney, J. M., Janssen, W. J. & Perraud, A. L. CD38 plays a dual role in allergen-induced airway hyperresponsiveness. Am 
J Respir Cell Mol Biol 40, 433–442, https://doi.org/10.1165/rcmb.2007-0392OC (2009).
 40. Schneider, M. et al. CD38 is expressed on inflammatory cells of the intestine and promotes intestinal inflammation. PLoS ONE 10, 
e0126007, https://doi.org/10.1371/journal.pone.0126007 (2015).
 41. Calvani, N. et al. Induction of apoptosis by the hydrocarbon oil pristane: implications for pristane-induced lupus. Journal of 
immunology 175, 4777–4782 (2005).
 42. Kahlenberg, J. M. et al. An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage. Arthritis 
Rheumatol 66, 152–162, https://doi.org/10.1002/art.38225 (2014).
 43. Tait, S. W. G. & Green, D. R. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11, 
621–632, http://www.nature.com/nrm/journal/v11/n9/suppinfo/nrm2952_S1.html (2010).
 44. Murphy, M. P. & Caraher, E. Mcl-1 is vital for neutrophil survival. Immunol Res 62, 225–233, https://doi.org/10.1007/s12026-015-
8655-z (2015).
 45. Nogueira, V. et al. Akt Determines Replicative Senescence and Oxidative or Oncogenic Premature Senescence and Sensitizes Cells 
to Oxidative Apoptosis. Cancer Cell 14, 458–470, https://doi.org/10.1016/j.ccr.2008.11.003 (2008).
 46. Chetram, M. A. et al. ROS-mediated activation of AKT induces apoptosis via pVHL in prostate cancer cells. Molecular and Cellular 
Biochemistry 376, 63–71, https://doi.org/10.1007/s11010-012-1549-7 (2013).
 47. Shack, S. et al. Caveolin-Induced Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway Increases Arsenite Cytotoxicity. 
Molecular and cellular biology 23, 2407–2414, https://doi.org/10.1128/mcb.23.7.2407-2414.2003 (2003).
 48. Suhara, T., Mano, T., Oliveira, B. E. & Walsh, K. Phosphatidylinositol 3-Kinase/Akt Signaling Controls Endothelial Cell Sensitivity 
to Fas-Mediated Apoptosis via Regulation of FLICE-Inhibitory Protein (FLIP). Circulation Research 89, 13–19, https://doi.
org/10.1161/hh1301.092506 (2001).
 49. Ono, K. et al. Contribution of caveolin-1α and Akt to TNF-α-induced cell death. American Journal of Physiology - Lung Cellular and 
Molecular Physiology 287, L201–L209, https://doi.org/10.1152/ajplung.00293.2003 (2004).
 50. Maddika, S. et al. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. Journal of 
Cell Science 121, 979–988, https://doi.org/10.1242/jcs.009530 (2008).
 51. Jeong, C.-H., Chun, K.-S., Kundu, J. & Park, B. Phosphorylation of Smac by Akt promotes the caspase-3 activation during etoposide-
induced apoptosis in HeLa cells. Molecular Carcinogenesis 54, 83–92, https://doi.org/10.1002/mc.22075 (2015).
 52. Knowles, H., Li, Y. & Perraud, A. L. The TRPM2 ion channel, an oxidative stress and metabolic sensor regulating innate immunity 
and inflammation. Immunol Res 55, 241–248, https://doi.org/10.1007/s12026-012-8373-8 (2013).
 53. Takahashi, N., Kozai, D., Kobayashi, R., Ebert, M. & Mori, Y. Roles of TRPM2 in oxidative stress. Cell Calcium 50, 279–287, https://
doi.org/10.1016/j.ceca.2011.04.006 (2011).
www.nature.com/scientificreports/
1 8SCIENTIFIC RepoRts |  (2018) 8:3357  | DOI:10.1038/s41598-018-21337-6
 54. Kolisek, M., Beck, A., Fleig, A. & Penner, R. Cyclic ADP-ribose and hydrogen peroxide synergize with ADP-ribose in the activation 
of TRPM2 channels. Molecular cell 18, 61–69, https://doi.org/10.1016/j.molcel.2005.02.033 (2005).
 55. Beck, A., Kolisek, M., Bagley, L. A., Fleig, A. & Penner, R. Nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose 
regulate TRPM2 channels in T lymphocytes. Faseb J 20, 962–964 (2006).
 56. Manna, P. T. et al. TRPM2-mediated intracellular Zn2+ release triggers pancreatic β-cell death. Biochemical Journal 466, 537–546, 
https://doi.org/10.1042/bj20140747 (2015).
 57. Tanuma, S. et al. New Insights into the Roles of NAD+ -Poly(ADP-ribose) Metabolism and Poly(ADP-ribose) Glycohydrolase. Curr 
Protein Pept Sci 17, 668–682 (2016).
 58. Botta, D. & Jacobson, M. K. Identification of a regulatory segment of poly(ADP-ribose) glycohydrolase. Biochemistry 49, 7674–7682, 
https://doi.org/10.1021/bi100973m (2010).
 59. Howard, M. et al. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science 262, 1056–1059 
(1993).
 60. Kim, H., Jacobson, E. L. & Jacobson, M. K. Synthesis and degradation of cyclic ADP-ribose by NAD glycohydrolases. Science 261, 
1330–1333 (1993).
 61. Jackson, D. G. & Bell, J. I. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an 
unusual discontinuous pattern of expression during lymphocyte differentiation. J. Immunol. 144, 2811–2815 (1990).
 62. Zhao, Y. J., Lam, C. M. & Lee, H. C. The membrane-bound enzyme CD38 exists in two opposing orientations. Sci Signal 5, ra67, 
https://doi.org/10.1126/scisignal.2002700 (2012).
 63. Liu, J. et al. Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels. Proceedings of the 
National Academy of Sciences of the United States of America, https://doi.org/10.1073/pnas.1703718114 (2017).
 64. Fliegert, R. et al. 2[prime]-Deoxyadenosine 5[prime]-diphosphoribose is an endogenous TRPM2 superagonist. Nature chemical 
biology 13, 1036–1044, https://doi.org/10.1038/nchembio.2415 http://www.nature.com/nchembio/journal/v13/n9/abs/
nchembio.2415.html#supplementary-information (2017).
 65. Rah, S. Y., Kwak, J. Y., Chung, Y. J. & Kim, U. H. ADP-ribose/TRPM2-mediated Ca2+ signaling is essential for cytolytic 
degranulation and antitumor activity of natural killer cells. Scientific reports 5, 9482, https://doi.org/10.1038/srep09482 (2015).
 66. Fenton, K. The effect of cell death in the initiation of lupus nephritis. Clinical and experimental immunology 179, 11–16, https://doi.
org/10.1111/cei.12417 (2015).
 67. Munoz, L. E., Lauber, K., Schiller, M., Manfredi, A. A. & Herrmann, M. The role of defective clearance of apoptotic cells in systemic 
autoimmunity. Nature reviews. Rheumatology 6, 280–289, https://doi.org/10.1038/nrrheum.2010.46 (2010).
 68. Han, S. et al. A Novel Subset of Anti-Inflammatory CD138+ Macrophages Is Deficient in Mice with Experimental Lupus. The 
Journal of Immunology. https://doi.org/10.4049/jimmunol.1700099 (2017).
 69. Ortega-Gómez, A., Perretti, M. & Soehnlein, O. Resolution of inflammation: an integrated view. EMBO Molecular Medicine 5, 
661–674, https://doi.org/10.1002/emmm.201202382 (2013).
 70. Potter, P. K., Cortes-Hernandez, J., Quartier, P., Botto, M. & Walport, M. J. Lupus-prone mice have an abnormal response to 
thioglycolate and an impaired clearance of apoptotic cells. Journal of immunology 170, 3223–3232 (2003).
 71. A-Gonzalez, N. et al. Apoptotic Cells Promote Their Own Clearance and Immune Tolerance through Activation of the Nuclear 
Receptor LXR. Immunity 31, 245–258, https://doi.org/10.1016/j.immuni.2009.06.018 (2009).
 72. Matalonga, J. et al. The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts 
Cellular NAD Metabolism. Cell Rep 18, 1241–1255, https://doi.org/10.1016/j.celrep.2017.01.007 (2017).
 73. Viegas, M. S., Silva, T., Monteiro, M. M., do Carmo, A. & Martins, T. C. Knocking out of CD38 accelerates development of a lupus-
like disease in lpr mice. Rheumatology 50, 1569–1577, https://doi.org/10.1093/rheumatology/ker178 (2011).
 74. Hubert, S. et al. Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway. J Exp 
Med 207, 2561–2568, https://doi.org/10.1084/jem.20091154 (2010).
 75. Scheuplein, F. et al. A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that 
upon activation inhibits autoimmune diabetes. Journal of autoimmunity 34, 145–154, https://doi.org/10.1016/j.jaut.2009.08.012, 
S0896-8411(09)00109-7 (2010).
 76. Rissiek, B., Haag, F., Boyer, O., Koch-Nolte, F. & Adriouch, S. ADP-ribosylation of P2X7: a matter of life and death for regulatory T 
cells and natural killer T cells. Curr Top Microbiol Immunol 384, 107–126, https://doi.org/10.1007/82_2014_420 (2015).
 77. Chen, Y. G. et al. CD38 is required for the peripheral survival of immunotolerogenic CD4+ invariant NK T cells in nonobese 
diabetic mice. Journal of immunology 177, 2939–2947 (2006).
 78. Driver, J. P. et al. Invariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian 
roulette. Diabetes 59, 423–432, https://doi.org/10.2337/db09-1116 (2010).
 79. Nacionales, D. C. et al. Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-
pentadecane (pristane). Am J Pathol 168, 1227–1240, https://doi.org/10.2353/ajpath.2006.050125 (2006).
 80. Cockayne, D. A. et al. Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral 
immune responses. Blood 92, 1324–1333 (1998).
 81. Ohlrogge, W. et al. Generation and characterization of ecto-ADP-ribosyltransferase ART2.1/ART2.2-deficient mice. Molecular and 
cellular biology 22, 7535–7542 (2002).
 82. Lischke, T. et al. CD8-beta ADP-ribosylation affects CD8(+) T-cell function. Eur J Immunol 43, 1828–1838, https://doi.org/10.1002/
eji.201243231 (2013).
 83. Koch-Nolte, F. et al. Mouse T cell membrane proteins Rt6-1 and Rt6-2 are arginine/protein mono(ADPribosyl)transferases and 
share secondary structure motifs with ADP-ribosylating bacterial toxins. J Biol Chem 271, 7686–7693 (1996).
 84. Yamamoto, S. et al. TRPM2-mediated Ca2+ influx induces chemokine production in monocytes that aggravates inflammatory 
neutrophil infiltration. Nat Med 14, 738–747, https://doi.org/10.1038/nm1758 (2008).
 85. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE 
guidelines for reporting animal research. PLoS Biol 8, e1000412, https://doi.org/10.1371/journal.pbio.1000412 (2010).
 86. Pavon, E. J. et al. Increased expression and phosphorylation of the two S100A9 isoforms in mononuclear cells from patients with 
systemic lupus erythematosus: A proteomic signature for circulating low-density granulocytes. Journal of proteomics 75, 1778–1791, 
https://doi.org/10.1016/j.jprot.2011.12.020, S1874-3919(11)00701-9 (2012).
 87. Mack, M. et al. Expression and Characterization of the Chemokine Receptors CCR2 and CCR5 in Mice. The Journal of Immunology 
166, 4697–4704, https://doi.org/10.4049/jimmunol.166.7.4697 (2001).
 88. Colella, A. D. et al. Comparison of Stain-Free gels with traditional immunoblot loading control methodology. Analytical 
biochemistry 430, 108–110, https://doi.org/10.1016/j.ab.2012.08.015 (2012).
 89. Gonzalez, J. et al. CD4+ CD25+ T cell-dependent inhibition of autoimmunity in transgenic mice overexpressing human Bcl-2 in T 
lymphocytes. Journal of immunology 178, 2778–2786 (2007).
 90. Lopez-Hoyos, M. et al. Constitutive expression of bcl-2 in B cells causes a lethal form of lupuslike autoimmune disease after 
induction of neonatal tolerance to H-2b alloantigens. J Exp Med 183, 2523–2531 (1996).
 91. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat Meth 9, 676–682, http://www.nature.com/nmeth/
journal/v9/n7/abs/nmeth.2019.html#supplementary-information (2012).
 92. Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3, 1101–1108 (2008).
www.nature.com/scientificreports/
1 9SCIENTIFIC RepoRts |  (2018) 8:3357  | DOI:10.1038/s41598-018-21337-6
 93. Dvinge, H. & Bertone, P. HTqPCR: high-throughput analysis and visualization of quantitative real-time PCR data in R. 
Bioinformatics 25, 3325–3326, https://doi.org/10.1093/bioinformatics/btp578 (2009).
 94. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, 
e47, https://doi.org/10.1093/nar/gkv007 (2015).
 95. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. & Golani, I. Controlling the false discovery rate in behavior genetics research. Behav 
Brain Res 125, 279–284 (2001).
 96. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta 
C(T)) Method. Methods 25, 402–408, https://doi.org/10.1006/meth.2001.1262, S1046-2023(01)91262-9 (2001).
Acknowledgements
We would like to thank Dr. Yasuo Mori for providing the Trpm2−/− mice, Clara Sánchez for animal husbandry 
at the IPBLN-CSIC Animal Facility, and Thomas S. Simpler and Uma Mudunuru for animal husbandry at the 
University of Alabama at Birmingham (UAB). We would also like to thank Laura Montosa from the Centro de 
Instrumentación Cientifica (CIC) at the Universidad de Granada (UGR) for technical support with microscopy, 
as well as Mohamed Tassi and Ana Santos at CIC, UGR, and Sandra García-Jiménez, Victoria Romero-del-Amo, 
Gemma Palencia-López, and Samuel Ruiz-Santiago at Campus Formación Granada for tissue preparations, 
H&E staining, and other staining procedures. Work performed in the Sancho lab was supported in part by the 
European Commission in collaboration with the following Funding Agencies: (i) Junta de Andalucía (J.A.), 
Consejería Innovación Ciencia y Empresa y Consejería Educación y Ciencia, Project: PC08-CTS-04046 to J.S. 
and M.Z., and (ii) Ministerio de Economía y Competitividad (MINECO), Projects: SAF-2011-27261 to J.S. and 
M.Z. and SAF2014-55088-R to R.M. Work performed in the Lund lab was supported by funds provided by UAB.
Author Contributions
S.G.R. and A.R.V. contributed equally to this work. S.G.R., A.R.V., D.B., L.C.R., E.Z., V.P.M., D.C.W., N.L.B., 
J.A.R.G., S.G. and E.G.P. performed experimental work and prepared Figures 1–3, 5–7, and the supplemental 
figures. DB performed the experiments depicted in Figs 3, S1 and S2. EAL analysed gene expression data generated 
by SGR and prepared Figs 4 and S4. SG supervised the flow cytometry acquisition process and performed the 
cell-sorting experiments. MM provided anti-CCR2 reagents and specific methodology for CCR2 detection by 
flow cytometry. FKN provided the Art2−/− and Cd38−/−Art2−/− double knockout mice and technical advice and 
reagents to isolate viable ART2-positive cells. A.C., F.E.L., R.M., M.Z. and J.S. designed the experiments. F.E.L. 
supervised the work of D.B. and E.Z., M.Z. and J.S. supervised jointly the work. J.S. wrote the main manuscript 
text. D.B. edited the manuscript. All authors reviewed the manuscript prior to submission.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-21337-6.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
